Novel 1,3-dicarbonyl derivative of aminobenzoic acid as a potential inhibitor of SARS-CoV-2 main protease (Mpro)

Basappa C  Yallur; Sampath Chinnam; Malathi Challa; Mithun Rudrapal; Sapana Jadoun; Sheetal R Batakurki; Vinayak Adimule; Siddhartha Maji; Ambika Madalakote Rajanna

Novel 1,3-dicarbonyl derivative of aminobenzoic acid as a potential inhibitor of SARS-CoV-2 main protease (Mpro)

Título traducido de la contribución: Nuevo derivado 1,3-dicarbonilo del ácido aminobenzoico como inhibidor potencial de la proteasa principal (Mpro) del SARS-CoV-2

Basappa C Yallur (Inventor)
, Sampath Chinnam (Inventor)
, Malathi Challa (Inventor)
, Mithun Rudrapal (Inventor)
, Sapana Jadoun (Inventor)
, Sheetal R Batakurki (Inventor)
, Vinayak Adimule (Inventor)
, Siddhartha Maji (Inventor)
, Ambika Madalakote Rajanna (Inventor)

Producción científica: Patente

Resumen

A cluster of pneumonia cases and COVID-19 pandemic that originated in Wuhan, China, was caused by novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). This has led to many number of deaths and many were infected worldwide owing to the absence of effective therapies against coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2). The current invention provides a promising and novel anti-SARS-CoV aminobenzoic acid analogue against SARS-CoV-2 main protease. The invention was performed in a facile, very simple, and a new synthetic route in shorter reaction times and good yields. The invention also delivers molecular docking calculations for the novel synthesized compound. In addition, drug-likeness properties of the new molecule was performed.

Título traducido de la contribución	Nuevo derivado 1,3-dicarbonilo del ácido aminobenzoico como inhibidor potencial de la proteasa principal (Mpro) del SARS-CoV-2
Idioma original	Inglés
Número de patente	02241019343 A
CIP	C01B 32/152000,C09K 19/020000,A61K 31/195000,G01S 5/100000,A61K 31/435000
Fecha de introducción	31/03/22
Estado	Publicada - 8 abr. 2022
Publicado de forma externa	Sí

Otros archivos y enlaces

Enlace a la Patente

Citar esto

@misc{f689763601b441efb93c3c36816c1b65,

title = "Novel 1,3-dicarbonyl derivative of aminobenzoic acid as a potential inhibitor of SARS-CoV-2 main protease (Mpro)",

abstract = "A cluster of pneumonia cases and COVID-19 pandemic that originated in Wuhan, China, was caused by novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). This has led to many number of deaths and many were infected worldwide owing to the absence of effective therapies against coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2). The current invention provides a promising and novel anti-SARS-CoV aminobenzoic acid analogue against SARS-CoV-2 main protease. The invention was performed in a facile, very simple, and a new synthetic route in shorter reaction times and good yields. The invention also delivers molecular docking calculations for the novel synthesized compound. In addition, drug-likeness properties of the new molecule was performed.",

author = "Yallur, \{Basappa C\} and Sampath Chinnam and Malathi Challa and Mithun Rudrapal and Sapana Jadoun and Batakurki, \{Sheetal R\} and Vinayak Adimule and Siddhartha Maji and Rajanna, \{Ambika Madalakote\}",

year = "2022",

month = apr,

day = "8",

language = "English",

publisher = "Indian Patent Office",

address = "India",

type = "Patent",

note = "02241019343 A; C01B 32/152000,C09K 19/020000,A61K 31/195000,G01S 5/100000,A61K 31/435000",

}

TY - PAT

T1 - Novel 1,3-dicarbonyl derivative of aminobenzoic acid as a potential inhibitor of SARS-CoV-2 main protease (Mpro)

AU - Yallur, Basappa C

AU - Chinnam, Sampath

AU - Challa, Malathi

AU - Rudrapal, Mithun

AU - Jadoun, Sapana

AU - Batakurki, Sheetal R

AU - Adimule, Vinayak

AU - Maji, Siddhartha

AU - Rajanna, Ambika Madalakote

PY - 2022/4/8

Y1 - 2022/4/8

N2 - A cluster of pneumonia cases and COVID-19 pandemic that originated in Wuhan, China, was caused by novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). This has led to many number of deaths and many were infected worldwide owing to the absence of effective therapies against coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2). The current invention provides a promising and novel anti-SARS-CoV aminobenzoic acid analogue against SARS-CoV-2 main protease. The invention was performed in a facile, very simple, and a new synthetic route in shorter reaction times and good yields. The invention also delivers molecular docking calculations for the novel synthesized compound. In addition, drug-likeness properties of the new molecule was performed.

AB - A cluster of pneumonia cases and COVID-19 pandemic that originated in Wuhan, China, was caused by novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). This has led to many number of deaths and many were infected worldwide owing to the absence of effective therapies against coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2). The current invention provides a promising and novel anti-SARS-CoV aminobenzoic acid analogue against SARS-CoV-2 main protease. The invention was performed in a facile, very simple, and a new synthetic route in shorter reaction times and good yields. The invention also delivers molecular docking calculations for the novel synthesized compound. In addition, drug-likeness properties of the new molecule was performed.

UR - https://www.researchgate.net/publication/359842630_Title_of_the_invention_Novel_13-dicarbonyl_derivative_of_aminobenzoic_acid_as_a_potential_inhibitor_of_SARS-CoV-2_main_protease_Mpro

M3 - Patent

M1 - 02241019343 A

Y2 - 2022/03/31

PB - Indian Patent Office

ER -